In vitro anti-glycation and anti-oxidant properties of synthesized schiff bases
Version: 1,
Uploaded by: Administrator,
Date Uploaded:
26 November 2022
Warning
You are about to be redirected to a website not operated by the Mauritius Research and Innovation Council. Kindly note that we are not responsible for the availability or content of the linked site. Are you sure you want to leave this page?
A series of mono, bis and mixed Schiff bases (1-7) were synthesised and evaluated for potential anti-glycation and anti-oxidant activities using the bovine serum albumin - glucose assay and 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical assay respectively. All compounds showed significant (p < 0.05) antiglycating activities with IC50 values (4.02 x10-24 ± 0.1 – 2.88 x 10-1 ± 1.35 mM) which were lower than the standard positive control aminoguanidine (IC50 : 1.51 x 10-3 ± 2.11 mM). Moreover, compounds 1-7 were found to possess significant (p < 0.05) DPPH radical scavenging properties with SC50 values (1.31 x 10-19 ± 0.05 to 2.25 x 10-1 ± 1.24 mM) lower than the standard ascorbic acid (SC50 : 5.50 x 10-3 ± 2.11 mM). Compound 6 was found to be the most potent anti-glycating molecule (IC50 value: 4.02 x10-24 ± 0.1 mM) while compound 5 was the most potent anti-oxidant molecule (SC50: 1.31 x 10-19 ± 0.05 mM); both being significantly lower (p < 0.05) than the respective positive controls used. The present data showed that the number of phenolic OH together with structural changes influence both the anti-glycation and anti-oxidant observed herein. This study provides for the first time a series of potential template molecules for possible pharmaceutical applications that warrant further investigation as potential anti-glycation and anti-oxidant agents which could be of importance in metabolic diseases including diabetes mellitus.
